HK Stock Market Move | LAEKNA-B(02105) rose by nearly 5%, company's self-developed new drug LAE120 received approval for clinical trials by the US FDA.

LAEKNA-B (02105) rose nearly 5%, as of press time, rose by 4.85% to HKD 13.4, with a turnover of HKD 33.6026 million. On the news front, Laike Pharmaceuticals announced yesterday that the U.S. Food and Drug Administration (FDA) has approved its independently developed LAE120, a new drug clinical trial application (IND) for a strong and highly selective USP1 inhibitor, for the treatment of late-stage solid tumor patients. The company stated that it is actively pursuing external collaborations to accelerate the clinical development progress of LAE120. In addition to LAE120, Laike's another independently developed potential anti-tumor drug, LAE118 (PI3K mutation selective inhibitor), has also entered the IND supporting research (IND-enabling) stage. Dr. Lv Xiangyang, CEO of Laike Pharmaceuticals, stated that the approval of another early-stage research project IND reflects Laike's strength in the field of new drug development. The company will continue to focus on the three major areas of obesity, tumors, and liver fibrosis, to advance and enrich its product pipeline.